LoneStar Heart Inc.
Addressing heart failure with an injectable biopolymer
This article was originally published in Start Up
LoneStar Heart's injectable biopolymer Algisyl-LVR represents a new advanced HF treatment strategy based on a medically accepted principle that a reduction in muscle tension and wall stress of the dilated heart will improve its function. The company, which originally envisioned Algisyl-LVR as a carrier for targeted delivery of biologics, drugs, or stem cells, discovered in animal studies that use of the biopolymer by itself had a profound effect on improving the mechanics of the heart.
You may also be interested in...
The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.
After some 10 years of the implementation of the EU’s Medical Device and IVD Regulations being an annual agenda item at December Council of the EU meetings, the scale of problems remains the same.